WORLD AIDS DAY: HIV market to grow as single-tablet regimens dominate
This article was originally published in Scrip
Executive Summary
On World AIDS Day 2014, Scrip takes a look at the future of the HIV market, and finds that it is set to grow by nearly 40% in the next nine years, driven by the arrival of more single-tablet regimens to rival Bristol-Myers Squibb/Gilead's Atripla (tenofovir disoproxil fumarate/emtricitabine/efavirenz).